DOI: http://dx.doi.org/10.18203/issn.2455-4529.IntJResDermatol20221204

Clobetasol propionate 0.025% cream in the management of steroid responsive dermatoses: an expert opinion

Jayakar Thomas, Abir Saraswat, Sanjeev Aurangabadkar, Roheet Rathod, Rahul Rathod, Amey Mane

Abstract


Topical corticosteroids play a key role in managing steroid responsive dermatoses (SRD). Current topical corticosteroid therapies are associated with various disadvantages. The current consensus article aims at providing a collation of evidence-based literature and clinical insights of the experts, regarding the efficacy, safety and usage of clobetasol propionate (CP) 0.025% cream in the management of SRD like plaque psoriasis. Clinical evidences suggest that the novel formulation of CP 0.025% cream has comparable efficacy and a better safety profile vs CP 0.05% cream in the management of plaque psoriasis. According to the doctors' experience, CP 0.025% can be used as first-line treatment for the management of SRD. In children 12-18-year-olds, CP 0.025% may be used cautiously, considering risk-benefit ratio. CP 0.025% may also be used as a maintenance therapy, after disease is brought under control with systemic therapy. Using moisturisers, salicylic acid, calcipotriol or tacrolimus as concomitant therapy with CP 0.025% cream may be beneficial in the management of SRD. In various comorbidities like diabetes and hypertension, CP 0.025% cream may be a better alternative verses CP 0.05% cream. Clinical evidences and experts suggest that for management of SRD, clobetasol propionate 0.025% cream can be recommended as a formulation with comparable efficacy and better safety profile versus CP 0.05% cream.


Keywords


Topical corticosteroids, Steroid responsive dermatoses, Clobetasol propionate

Full Text:

PDF

References


Del Rosso JQ. Topical Corticosteroid Therapy for Psoriasis-A Review of CP 0.025% Cream and the Clinical Relevance of Penetration Modification. J Clin Aesthet Dermatol. 2020;13(2):22-9.

Gabros S, Nessel TA, Zito PM. Topical Corticosteroids. In: StatPearls. Treasure Island (FL): StatPearls. 2021. Available at: https://www.ncbi.nlm.nih.gov/books/NBK532940/. Accessed on 20 December 2021.

Uva L, Miguel D, Pinheiro C, Antunes J, Cruz D, Ferreira J. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:561018.

Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: A long overdue revisit. Indian Dermatol Online J. 2014;5(4):416-25.

Shenoy MM, Jayarama J. Epidemic of Difficult-to-Treat Tinea in India: Current Scenario, Culprits, and Curbing Strategies. Arch Med Health Sci. 2019;7:112-7.

Pels R, Sterry W, Lademann J. CP--where, when, why?. Drugs Today (Barc). 2008;44(7):547-57.

Melian EB, Spencer CM, Jarvis B. CP foam, 0.05%. Am J Clin Dermatol. 2001;2(2):89-92.

Sidgiddi S, Naqvi SMH, Shenoy M, Balraj DN, Kothari J, Gupta S et al. Efficacy and Safety of Novel Formulation of CP 0.025% Cream in Indian Moderate-toSevere Psoriasis Patients: Phase-2a, Randomized 3-Arm Study. Dermatol Ther (Heidelb). 2021;11:1717-23.

Draelos ZD, Fowler JF, Cornelison R. A Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing with Clobetasol Propionate Cream (Impoyz™), 0.025% versus Clobetasol Propionate (Temovate®) Cream, 0.05% in Subjects with Moderate to Severe Plaque Psoriasis. The National Society for Cutaneous Medicine. 2018;2(6):410-20.

Highlights of prescribing information for IMPOYZ (clobetasol propionate) Cream, 0.025%, 2021. Available at: https://www.accessdata.fda.gov/ drugsatfda_docs/label/2017/209483s000lbl.pdf. Accessed on 30 August 2021.

Purnamawati S, Indrastuti N, Danarti R, Saefudin T. The Role of Moisturizers in Addressing Various Kinds of Dermatitis: A Review. Clin Med Res. 2017;15(3-4):75-87.

Austad J, Bjerke JR, Gjertsen BT, Helland S, Livden JK, Morken T et al. CP followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis. J Eur Acad Dermatol Venereol. 1998;11(1):19-24.

Sisti A, Sisti G, Oranges CM. Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review. An Bras Dermatol. 2016;91(2):187-95.

Psoriasis treatment: Tacrolimus ointment and pimecrolimus cream,2021. Available at: https://www.aad.org/public/diseases/psoriasis/treatment/medications/tacrolimus. Accessed on 30 August 2021.

Chamani G, Rad M, Zarei MR, Lotfi S, Sadeghi M, Ahmadi Z. Tacrolimus or clobetasol for treatment of oral lichen planus. Evidence-Based Dentistry. 2016;17:16.